Alexion Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Raised to $122 at Jefferies Following 3Q
October 27, 2017 8:45 AM EDTJefferies raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $122.00 (from $121.00) while maintaining a Hold rating following the company's 3Q. ~In-line Soliris sales of ~$756M offset by lower non-GAAP OpEx and taxes, resulted in higher non-GAAP EPS of $1.44 (vs. consensus of... More
Alexion Pharma (ALXN) Tops Q3 EPS by 12c, Sales Miss; Bumps Outlook
October 26, 2017 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.44, $0.12 better than the analyst estimate of $1.32. Revenue for the quarter came in at $859 million versus the consensus estimate of $864.45 million.
GUIDANCE:
Alexion Pharma sees FY2017 EPS of $5.50-$5.65, versus prior of $5.40-$5.55... More
